Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2023

Najima Yuho

Abstract excerpt

FMS-like tyrosine kinase 3 (FLT3) mutation is present in 25% of acute myeloid leukemia (AML) cases. It is associated with poor prognosis due to a high relapse rate and short remission duration. Consequently, various FLT3 inhibitors were developed. Two second-generation FLT3 inhibitors, including...

Topics

Humans
fms-Like Tyrosine Kinase 3
Phenylurea Compounds
Mutation
Recurrence
Leukemia, Myeloid, Acute
Protein Kinase Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 37793868
DOI: 10.11406/rinketsu.64.932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-37793868-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].PMID 37793868Read ↗

[Pathogenesis and treatment of acute myeloid leukemia with FLT3 mutations].Semantic proximity Read ↗

[Current status and challenges of AML treatment with FLT3 inhibitors].Semantic proximity Read ↗

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.Semantic proximity Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

Targeting FLT3 Mutations in Acute Myeloid LeukemiaSemantic proximity Read ↗

A review of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

[FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].Semantic proximity Read ↗

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Semantic proximity Read ↗

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.